Form 4: VOLITIONRX CEO Buys Shares in Direct Offering

VolitionRx Ltd. President and CEO Cameron John Reynolds acquired 78,125 shares of common stock at $0.64 per share in a registered direct offering.

Summary

• Cameron John Reynolds, President and CEO of VolitionRx Ltd. (VNRX), acquired 78,125 shares of common stock.
• The acquisition occurred on August 5, 2025, at an offering price of $0.64 per share.
• This transaction was part of a registered direct offering by VolitionRx.
• Following the transaction, Mr. Reynolds directly owns 2,609,847 shares.
• He also indirectly owns 1,007,718 shares through Concord International, Inc., where he is the majority shareholder, and 34,076 shares through his spouse.

Sentiment

Score: 8

Explanation: The acquisition of shares by the CEO, especially as part of a direct offering, is a strong positive signal of confidence in the company's future and its current valuation.

Positives

• Insider buying by the President and CEO signals confidence in the company's future prospects.
• The acquisition was made at the offering price in a registered direct offering, indicating participation in a broader capital raise.

Future Outlook

The filing does not provide specific forward-looking statements or guidance beyond the transaction details.

Industry Context

This insider purchase reflects a common practice where executives invest in their own company, often signaling confidence. The specific context of a 'registered direct offering' suggests a capital raise, which is a broader industry trend for companies seeking to fund operations or growth.

Related Party Transactions

• Cameron John Reynolds indirectly owns 1,007,718 shares through Concord International, Inc., where he is the majority shareholder and shares voting and dispositive control.

Stakeholder Impact

• Shareholders may view this insider purchase as a positive sign of management's belief in the company's value, potentially increasing investor confidence.
• The capital raise implied by the 'registered direct offering' could impact existing shareholders through dilution, though the CEO's participation might mitigate some concerns.

Key Dates

Recommendation

The President and CEO's direct purchase of a significant number of shares at the offering price in a registered direct offering is a strong vote of confidence, aligning management's interests with shareholders. This insider buying often signals that management believes the stock is undervalued or has significant upside potential, making it an attractive opportunity for investors.

Keywords

VolitionRx, VNRX, Insider Trading, Form 4, Share Acquisition, CEO, Cameron John Reynolds, Direct Offering, Equity